



“Monitoring latent tuberculosis infection diagnosis and management in the Netherlands.” Connie G.M. Erkens, Erika Slump, Maurits Verhagen, Henrieke Schimmel, Gerard de Vries, Frank Cobelens and Susan van den Hof. *Eur Respir J* 2016; 47: 1492–1501.

This article from the May 2016 issue of the *European Respiratory Journal* was published with some errors in the data from table 2, specifically that regarding the numbers of foreign-born and Dutch-born persons with latent tuberculosis infection (and those of unknown origin) who did or did not initiate preventive treatment. These errors do not have any effect on the values of the univariate and multivariable analyses presented for these entries in the table. The corrected table is as follows:

TABLE 2 Univariable and multivariable analysis of determinants of preventive treatment initiation in persons notified with latent tuberculosis (TB) infection initiated on preventive treatment

	Preventive treatment initiation		Univariable		Multivariable	
	No	Yes [#]	OR (95% CI)	p-value	aOR (95% CI)	p-value
Total	8798	28 931 (77)				
Period						
1993–1996	473	5860 (93)	4.3 (3.8–4.8)	<0.001	1.9 (1.3–3.1)	0.002
1997–2000	1548	6370 (80)	1.4 (1.3–1.5)	<0.001	0.69 (0.45–1.6)	0.09
2001–2004	2541	6352 (71)	0.87 (0.80–0.93)	<0.001	0.45 (0.29–0.69)	<0.001
2005–2008	2471	5235 (68)	0.73 (0.68–0.79)	<0.001	0.65 (0.59–0.72)	<0.001
2009–2013	1765	5114 (74)	1.0		1.0	
Age group years						
0–14	148	3153 (96)	1.0		1.0	
15–24	1677	8891 (84)	0.25 (0.21–0.30)	<0.001	0.26 (0.22–0.31)	<0.001
25–34	1811	7207 (80)	0.19 (0.16–0.22)	<0.001	0.18 (0.15–0.21)	<0.001
35–44	1921	5292 (73)	0.13 (0.11–0.15)	<0.001	0.11 (0.10–0.14)	<0.001
45–54	2232	3250 (59)	0.07 (0.06–0.08)	<0.001	0.06 (0.05–0.07)	<0.001
55–64	884	906 (51)	0.05 (0.04–0.06)	<0.001	0.04 (0.04–0.05)	<0.001
≥65	125	232 (65)	0.09 (0.07–0.11)	<0.001	0.05 (0.03–0.06)	<0.001
Sex						
Male	4506	14 222 (76)	1.0		1.0	
Female	4289	14 688 (77)	1.1 (1.0–1.1)	0.001	1.1 (1.0–1.1)	0.002
Residence						
Urban	1806	6478 (78)	1.0			
Rural	6992	22 453 (76)	0.90 (0.84–0.95)	<0.001		
Origin						
Foreign born	1579	4659 (75)	1.0		1.0	
Dutch born	7131	24 057 (77)	1.1 (1.1–1.2)	<0.001	1.1 (0.98–1.2)	0.11
Unknown	88	215 (71)	0.82 (0.63–1.1)	0.12	0.75 (0.56–1.0)	0.05
BCG vaccination						
No BCG	6990	24 785 (78)	1.0	<0.001	1.0	
BCG	1050	2575 (71)	0.69 (0.64–0.75)	<0.001	0.79 (0.71–0.88)	<0.001
Unknown	758	1571 (67)	0.58 (0.53–0.64)	<0.001	0.66 (0.60–0.74)	<0.001
Diagnostic test						
TST	2792	6762 (71)	1.0		1.0	<0.001
IGRA	256	453 (64)	0.73 (0.62–0.86)	<0.001	0.79 (0.65–0.96)	0.02
TST and IGRA	1169	2998 (72)	1.1 (0.98–1.2)	0.16	1.1 (0.98–1.2)	0.10
Unknown	4581	18 718 (80)	1.7 (1.6–1.8)	<0.001	1.7 (1.1–2.6)	0.02

Continued

TABLE 2 Continued

	Preventive treatment initiation		Univariable		Multivariable	
	No	Yes [#]	OR (95% CI)	p-value	aOR (95% CI)	p-value
Target group						
TB contact	4705	18 214 (79)	1.0	<0.001	1.0	<0.001
Immunosuppression	42	779 (95)	4.8 (3.5–6.5)	<0.001	13.8 (9.9–19.1)	<0.001
Pre-exposure examination	2252	5014 (69)	0.58 (0.54–0.61)	<0.001	0.49 (0.46–0.52)	<0.001
Professional at risk [¶]	220	391 (64)	0.46 (0.39–0.54)	<0.001	0.62 (0.51–0.74)	<0.001
Traveller [¶]	258	563 (69)	0.56 (0.48–0.66)	<0.001	0.55 (0.46–0.65)	<0.001
Other post-exposure	1297	3856 (75)	0.77 (0.72–0.82)	<0.001	0.53 (0.49–0.57)	<0.001
Fibrotic lesions	24	114 (83)	1.2 (0.79–1.9)	0.36	2.1 (1.3–3.4)	0.002

Data are presented as n or n (%), unless otherwise stated. OR: odds ratio; aOR: adjusted OR; BCG: bacille Calmette-Guérin; TST: tuberculin skin test; IGRA: interferon- γ release assay. [#]: percentage treatment initiated of row total given in parentheses; [¶]: post-exposure.

The article has been corrected and republished online.

Copyright ©ERS 2017